Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates
Sage Therapeutics, Inc. (NASDAQ: SAGE) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.16. This compares to loss of $1.83 per share a year ago. These figures are adjusted for non-recurring items.
The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: firstname.lastname@example.org